2 results about "RELA" patented technology

This invention provides an L-homoserine-producing strain, its construction method, and its applications. The strain does not contain plasmids. E.coli W3110, as a chassis strain, had the relA and thrB genes knocked out, and heterologously expressed genes derived from... Clostridium acetobutylicum The gapC gene and the aspB gene derived from Bacillus subtilis were overexpressed, along with ppc, asd, and thrA. fbr ,rhtA,pntAB,spoT fbr Genes; the strain described above can effectively improve the L-homoserine synthesis efficiency by knocking out genes of the L-homoserine degradation pathway, enhancing the expression of key enzymes in the pathway, optimizing the L-homoserine transport system, increasing the reducing power NADPH content, and enhancing the ability to withstand amino acid starvation. It is genetically stable, requires no addition of resistance substances, has high acid production efficiency, and has good L-homoserine synthesis capacity.

The invention discloses a recombinant engineering bacterium, a preparation method thereof and application of the recombinant engineering bacterium in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The recombinant engineering bacterium is prepared by taking salmonella typhimurium with relA and spoT gene mutations as a carrier and introducing a recombinant plasmid containing a thrombolytic enzyme coding gene into the carrier. The invention provides a recombinant engineering bacterium with biological safety, the recombinant engineering bacterium has high thrombus targeting property under a dynamic blood flow condition, various thrombus models can be specifically targeted, and the concentration of the recombinant engineering bacterium in thrombus tissues can reach more than ten thousand times of the concentration of normal tissues such as spleen, liver and the like through bacterium proliferation. Through mediated thrombus targeted therapy, thrombus can be effectively dissolved, and revascularization is achieved. The invention provides a more effective and safer treatment strategy for diseases caused by thrombus, such as myocardial infarction, cerebral apoplexy, pulmonary embolism and the like.